CPO
SUPN icon

Cerity Partners OCIO’s Supernus Pharmaceuticals SUPN Stock Holding History

Cerity Partners OCIO’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-13,031
Closed -$272K – 375
2020
Q3 		$272K Buy
+13,031
New +$296K 0.01% 305

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return

Cerity Partners OCIO's SUPN Position: Q4 2020 in Review

Cerity Partners OCIO sold out of Supernus Pharmaceuticals (SUPN) in Q4 2020, closing a stake of 13,031 shares — an estimated $272K sold.

Cerity Partners OCIO first reported a position in SUPN in Q3 2020 and held it in 1 quarter. The position peaked at $272K in Q3 2020. 225 funds tracked by Wall St. Rank hold SUPN as of Q4 2020.

  • Cerity Partners OCIO reported no remaining Supernus Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Cerity Partners OCIO sold 13,031 Supernus Pharmaceuticals shares in Q4 2020, an estimated $272K.
  • Cerity Partners OCIO first reported a position in Supernus Pharmaceuticals in Q3 2020 and held it in 1 quarter.
  • Cerity Partners OCIO's Supernus Pharmaceuticals position peaked at $272K in Q3 2020.
  • 225 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2020.

Based on Cerity Partners OCIO's 13F filing for Q4 2020, filed 10 Feb 2021.